check_circleStudy Completed

Dermatitis, Photoallergic

Bayer Identifier:

18155

ClinicalTrials.gov Identifier:

NCT04532164

EudraCT Number:

Not Available

EU CT Number:

Not Available
Study to find out if cream V61-044 used to treat fungal infections causes an allergic skin reaction to sunlight in healthy participants

Trial purpose

Allergic skin reaction can be produced by the combination of a chemical product applied to the skin and ultraviolet (UV) radiation (a type of invisible light that comes from the sun and other light sources and can hurt your skin and eyes) received by the person. The researchers in this study wanted to find out if cream V61-044 might cause an allergic skin reaction to sunlight when applied to the skin in healthy participants. Cream V61-044 (brand name: LOTRIMIN ULTRA) is an approved drug used to treat infections caused by fungi (small growing organisms such as mold, mildew, yeast or mushrooms).
Participants joining this study underwent two study phases: in Induction phase, participants received the test cream and UV radiation twice a week for 3 weeks; after 10 days of rest, in Challenge phase participants received the test cream and UV radiation once again. In both phases, the test cream was applied to two test areas on the upper back of the participants and to one of the test area UV radiation was applied. Evaluation on the skin rash was conducted two days after each UV radiation.

Key Participants Requirements

Sex

All

Age

18 - 60 Years
  • - Subjects must have been between the ages of 18 and 60 years;
    - Subjects must have been lightly pigmented with skin phototypes I - III, determined by the following guidelines: I-Always burns easily; never tans (sensitive); II-Always burns easily; tans minimally (sensitive); III-Burns moderately; tans gradually (light-brown) (normal);
    - Subjects must have been in general good health as determined by the subject’s medical history;
    - Subjects must have been willing to avoid tanning bed usage and additional sun exposure during the study and follow-up period;
    - Subjects must have been willing to refrain from using any new topical products during the trial;
    - Subjects must have been able and willing to cooperate with the Investigator and research staff, to have test materials applied according to protocol, and to complete the full course of the trial;
    - Subjects must have been willing to report any medications taken during the trial and refrain from taking any medications during the trial that might produce photoreactions;
    - If female, produced a negative urine pregnancy test prior to the initiation and also at the completion of the study.
  • - Subjects with a visible sunburn;
    - Subjects who had a history of sun hypersensitivity, photosensitivity, or photosensitive dermatoses;
    - Subjects with a history of allergies or sensitivities to cosmetics, toiletries, or any dermatological products;
    - Subjects who had recently used any systemic or topical drugs which can cause a photoreaction or may interfere with the trial;
    - Subjects with any known skin conditions that might have interfered with the proper conduct of the trial;
    - Subjects with scars, moles, excessive hair, or other blemishes over the mid or lower back which might have interfered with the test or the grading of the test sites;
    - Subjects who had significant history of internal disease that may have interfered with the evaluation of the test material as determined by the Investigator;
    - Female subjects who were pregnant, planning pregnancy, or nursing a child during the study period;
    - Subjects who had used a tanning bed or other artificial tanning lights within the past two months;
    - Subjects who had participated in a patch test involving the back within four weeks prior to the start of the trial;
    - Subjects who would concurrently participate in any other clinical or consumer test;
    - Subjects who had other conditions considered by the Investigator as sound reasons for disqualification from enrollment into the trial.

Trial summary

Enrollment Goal
137
Trial Dates
June 2013 - November 2013
Phase
Phase 3
Could I Receive a placebo
No
Products
LOTRIMIN ULTRA (Butenafine HCl, BAY1896425)
Accepts Healthy Volunteer
Yes

Where to participate

StatusInstitutionLocation
Completed
Fairfield, 07004, United States

Primary Outcome

  • Photoallergic reaction evaluation reported as number of test site with different erythema score during Challenge Phase - All treated subjects
    Evaluation of the test sites after irradiation used following scoring system: score 0=normal skin (no visible reaction); score 1= faint, barely perceptible to moderate redness with poorly defined margins (not clinically significant); score 2=moderate to intense redness with well defined margins; score 3=redness with well defined edema; score 4=redness with papules, vesicles, or ulceration. During Challenge Phase, each subject had the following four virgin test sites: Treated irradiated test site; Treated non-irradiated test site; Untreated irradiated test site; Untreated non-irradiated test site. All four test sites were evaluated according to the above scoring system at 24, 48, and 72 hours following patch application (3 different time points), and the number of test sites with available scores from all these time points were reported for all treated subjects.
    date_rangeTime Frame:
    At 24, 48, and 72 hours following patch application
  • Photoallergic reaction evaluation reported as number of test site with different erythema score during Challenge Phase - All evaluable subjects
    Evaluation of the test sites after irradiation used following scoring system: score 0=normal skin (no visible reaction); score 1= faint, barely perceptible to moderate redness with poorly defined margins (not clinically significant); score 2=moderate to intense redness with well defined margins; score 3=redness with well defined edema; score 4=redness with papules, vesicles, or ulceration. During Challenge Phase, each subject had the following four virgin test sites: Treated irradiated test site; Treated non-irradiated test site; Untreated irradiated test site; Untreated non-irradiated test site. All four test sites were evaluated according to the above scoring system at 24, 48, and 72 hours following patch application (3 different time points), and the number of test sites with available scores from all these time points were reported for all evaluable subjects.
    date_rangeTime Frame:
    At 24, 48, and 72 hours following patch application

Secondary Outcome

  • Development of erythema on treated irradiated test sites during Induction Phase - All treated subjects
    Evaluation of the test sites after irradiation used following scoring system: score 0=normal skin (no visible reaction); score 1= faint, barely perceptible to moderate redness with poorly defined margins (not clinically significant); score 2=moderate to intense redness with well defined margins; score 3=redness with well defined edema; score 4=redness with papules, vesicles, or ulceration. During Induction Phase, each subject had the following two test sites: Treated irradiated test site and Treated non-irradiated test site. The number of test sites with available scores from all 6 induction patches were reported for all treated subjects.
    date_rangeTime Frame:
    Two or three days after each irradiation during Induction Phase
  • Development of erythema on the treated non-irradiated test sites during Induction Phase - All treated subjects
    Evaluation of the test sites after irradiation used following scoring system: score 0=normal skin (no visible reaction); score 1= faint, barely perceptible to moderate redness with poorly defined margins (not clinically significant); score 2=moderate to intense redness with well defined margins; score 3=redness with well defined edema; score 4=redness with papules, vesicles, or ulceration. During Induction Phase, each subject had the following two test sites: Treated irradiated test site and Treated non-irradiated test site. The mean score of test sites with available scores from all 6 induction patches were reported for all treated subjects.
    date_rangeTime Frame:
    Two or three days after each irradiation during Induction Phase
  • Development of erythema on the treated non-irradiated test sites during Challenge Phase reported as number of test site with different erythema score - All treated subjects
    Evaluation of the test sites after irradiation used following scoring system: score 0=normal skin (no visible reaction); score 1= faint, barely perceptible to moderate redness with poorly defined margins (not clinically significant); score 2=moderate to intense redness with well defined margins; score 3=redness with well defined edema; score 4=redness with papules, vesicles, or ulceration. During Challenge Phase, each subject had the following four virgin test sites: Treated irradiated test site; Treated non-irradiated test site; Untreated irradiated test site; Untreated non-irradiated test site. All four test sites were evaluated according to the above scoring system at 24, 48, and 72 hours following patch application (3 different time points), and the number of test sites with available scores from all these time points were reported for all treated subjects.
    date_rangeTime Frame:
    At 24, 48, and 72 hours following patch application
  • Development of erythema on treated irradiated test sites during Induction Phase - All evaluable subjects
    Evaluation of the test sites after irradiation used following scoring system: score 0=normal skin (no visible reaction); score 1= faint, barely perceptible to moderate redness with poorly defined margins (not clinically significant); score 2=moderate to intense redness with well defined margins; score 3=redness with well defined edema; score 4=redness with papules, vesicles, or ulceration. During Induction Phase, each subject had the following two test sites: Treated irradiated test site and Treated non-irradiated test site. The number of test sites with available scores from all 6 induction patches were reported for all evaluable subjects.
    date_rangeTime Frame:
    Two or three days after each irradiation during Induction Phase
  • Development of erythema on the treated non-irradiated test sites during Induction Phase - All evaluable subjects
    Evaluation of the test sites after irradiation used following scoring system: score 0=normal skin (no visible reaction); score 1= faint, barely perceptible to moderate redness with poorly defined margins (not clinically significant); score 2=moderate to intense redness with well defined margins; score 3=redness with well defined edema; score 4=redness with papules, vesicles, or ulceration. During Induction Phase, each subject had the following two test sites: Treated irradiated test site and Treated non-irradiated test site. The mean score of test sites with available scores from all 6 induction patches were reported for all evaluable subjects.
    date_rangeTime Frame:
    Two or three days after each irradiation during Induction Phase
  • Development of erythema on the treated non-irradiated test sites during Challenge Phase reported as number of test site with different erythema score - All evaluable subjects
    Evaluation of the test sites after irradiation used following scoring system: score 0=normal skin (no visible reaction); score 1= faint, barely perceptible to moderate redness with poorly defined margins (not clinically significant); score 2=moderate to intense redness with well defined margins; score 3=redness with well defined edema; score 4=redness with papules, vesicles, or ulceration. During Challenge Phase, each subject had the following four virgin test sites: Treated irradiated test site; Treated non-irradiated test site; Untreated irradiated test site; Untreated non-irradiated test site. All four test sites were evaluated according to the above scoring system at 24, 48, and 72 hours following patch application (3 different time points), and the number of test sites with available scores from all these time points were reported for all evaluable subjects.
    date_rangeTime Frame:
    At 24, 48, and 72 hours following patch application

Trial design

HT201309- Human Photoallergy Test
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
N/A
Blinding
N/A
Assignment
Single Group Assignment
Trial Arms
1

Additional Information

Click here to find results for studies related to Bayer Healthcare products.